Lupin shines on launching Diazepam Rectal Gel in United States
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 1191.90, up by 22.55 points or 1.93% from its previous closing of Rs. 1169.35 on the BSE.
The scrip opened at Rs. 1173.75 and has touched a high and low of Rs. 1201.00 and Rs. 1173.75 respectively. So far 14158 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1215.20 on 17-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1201.00 and Rs. 1113.00 respectively. The current market cap of the company is Rs. 53233.57 crore.
The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.
Lupin has launched Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System, after its wholly owned subsidiary, Novel Laboratories Inc., based in Somerset, New Jersey received an approval for its ANDA from the United States Food and Drug Administration (USFDA).
Diazepam Rectal Gel, 10 mg and 20 mg, Rectal Delivery System is the generic version of Diastat AcuDial Rectal Delivery System, 10 mg and 20 mg, of Bausch Health US, LLC. Diazepam Rectal Gel (RLD Diastat AcuDial) had estimated annual sales of $37 million in the U.S. (IQVIA MAT September 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
